home / stock / kymr / kymr quote
Last: | $33.97 |
---|---|
Change Percent: | 0.4% |
Open: | $34.98 |
Close: | $33.97 |
High: | $35.53 |
Low: | $33.35 |
Volume: | 627,447 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$33.97 | $34.98 | $33.97 | $35.53 | $33.35 | 627,447 | 04-19-2024 |
$35.12 | $33.67 | $35.12 | $35.57 | $33.67 | 619,729 | 04-18-2024 |
$33.76 | $34.39 | $33.76 | $34.41 | $33.17 | 433,665 | 04-17-2024 |
$33.93 | $33.78 | $33.93 | $34.76 | $33.58 | 492,350 | 04-16-2024 |
$34.39 | $35.81 | $34.39 | $35.82 | $34.2 | 528,869 | 04-15-2024 |
$35.58 | $36.81 | $35.58 | $36.92 | $34.745 | 598,100 | 04-12-2024 |
$37.21 | $35.61 | $37.21 | $37.32 | $35.43 | 469,853 | 04-11-2024 |
$35.33 | $35.72 | $35.33 | $36.43 | $35.07 | 655,356 | 04-10-2024 |
$37.61 | $36.53 | $37.61 | $37.64 | $35.975 | 494,951 | 04-09-2024 |
$36.37 | $36.7 | $36.37 | $37.18 | $35.88 | 296,257 | 04-08-2024 |
$36.4 | $36.07 | $36.4 | $37.16 | $35.27 | 428,984 | 04-05-2024 |
$36.24 | $37.42 | $36.24 | $38.05 | $36.035 | 471,942 | 04-04-2024 |
$37.13 | $37.27 | $37.13 | $38.09 | $36.59 | 591,871 | 04-03-2024 |
$37.64 | $38.26 | $37.64 | $38.66 | $36.755 | 543,257 | 04-02-2024 |
$39.42 | $40.34 | $39.42 | $40.55 | $38.21 | 528,312 | 04-01-2024 |
$40.2 | $40.22 | $40.2 | $40.62 | $39.34 | 544,045 | 03-29-2024 |
$40.2 | $40.22 | $40.2 | $40.62 | $39.34 | 544,045 | 03-28-2024 |
$40.17 | $39.98 | $40.17 | $40.21 | $38.96 | 670,966 | 03-27-2024 |
$39.49 | $40 | $39.49 | $40.36 | $38.99 | 382,439 | 03-26-2024 |
$39.5 | $40.63 | $39.5 | $41.33 | $39.28 | 302,085 | 03-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR’s late-breaking poster session Nello Mainolfi, Founder, President and CEO of Kymera, invited as a featured speaker in AACR’s Major Symposium to...
KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity with oral small molecule profiles KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in first half of 2025, both with Phase 1 data in 20...
2024-03-03 07:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...